Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

SciSparc Ltd. - Ordinary Shares (NQ:SPRC)

0.3040 +0.0231 (+8.22%)
Streaming Delayed Price Updated: 3:58 PM EDT, Apr 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about SciSparc Ltd. - Ordinary Shares

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Why Kalera Shares Are Trading Lower By Around 37%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Innovative Eyewear, Inc. (NASDAQ: LUCY) jumped 164% to $3.86 after the company announced it launched ChatGPT-enabled smart eyewear. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
We're starting off the day with a breakdown of the biggest pre-market stock movers traders will want to keep an eye on Tuesday! 
Via InvestorPlace
Update: SciSparc To Spin Off Pharmaceutical Activities Into New Subsidiary
The jury is out on how well SciSparc will do in executing its restructuring plan, but the company has no other choice. 
Via Talk Markets
SciSparc Receives Final Approval to Commence its Phase IIb Clinical Trial for SCI-110 to treat Tourette Syndrome
From SciSparc Ltd
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Friday
  On Friday, 93 stocks made new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  During Tuesday, 95 stocks hit new 52-week lows. 
Via Benzinga
SciSparc completes the sale of a 49% interest in its Subsidiary that owns Wellution for $3 million
From SciSparc Ltd
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Welcome back and get ready for another day of trading with a breakdown of the biggest pre-market stock movers for Monday! 
Via InvestorPlace
SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification
From SciSparc Ltd
Via GlobeNewswire
SciSparc Receives Approval to conduct its Phase IIb Clinical Trial for SCI-110 to treat Tourette Syndrome
From SciSparc Ltd
Via GlobeNewswire
SciSparc Completes Production Of Its Dronabinol-Based Drug Candidate For Its Clinical Trial On Tourette Syndrome
SciSparc Ltd. (NASDAQ: SPRC) has successfully manufactured clinical batches of its drug candidate SCI-110 to be used in its upcoming multinational, multicenter, phase IIb trial for Tourette syndrome. 
Via Benzinga
SciSparc Successfully Completed Production of its Proprietary Drug Candidate SCI-110 for its Upcoming Clinical Trial On Tourette Syndrome
From SciSparc Ltd
Via GlobeNewswire
Psyched: Hawaii And Minnesota's Bills, Studying 2C-B Vs. Psilocybin, Filament CEO, Plus Brock Pierce And Jeremy Gardner Discuss The Industry's Future And More
Two Bills Approved By Hawaii Senators With Governor's Endorsement Hawaii Senate Ways and Means Committee approved a pair of bills aiming to promote and investigate the therapeutic potential of MDMA and... 
Via Benzinga
SciSparc's CBD-Based Drug One Step Closer To Clinical Trial On Children With Autism Spectrum Disorder
SciSparc Ltd. (NASDAQ: SPRC) has signed an agreement with Israel's manufacturer and distributor of cannabis-based products, Tikun Olam Cannbit Pharmaceuticals Ltd., Israel (TASE:TKUN), to supply... 
Via Benzinga
SciSparc Signs Agreement for the Supply of CBD-rich Cannabis Oil for its Clinical Trial on Children with Autism Spectrum Disorder
From SciSparc Ltd
Via GlobeNewswire
Jeffs' Brands To Acquire A 49% Interest In A Company That Owns A Top Seller Brand On Amazon For $2.5M
Jeffs' Brands Ltd (NASDAQ: JFBR), a data-driven e-commerce company operating on the Amazon Marketplace, has entered into a definitive agreement with SciSparc Ltd. 
Via Benzinga
Jeffs' Brands Entered into a Definitive Agreement to Acquire a 49% interest in a company that Owns Wellution, a Top Seller Brand on Amazon for $2.5 million
From Jeffs' Brands Ltd
Via GlobeNewswire
SciSparc Signs a Definitive Agreement to Sell 49% interest in its Subsidiary that Owns Wellution for $2.5 million
From SciSparc Ltd
Via GlobeNewswire
SciSparc And Clearmind Reveal Three Unique Combinations Of Future Psychedelic-Based Compounds
SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced that as part of its... 
Via Benzinga
SciSparc and Clearmind Reveal Three Unique Combinations of Future Psychedelic-Based Compounds
Clearmind Medicine submitted patent applications to protect the novel compounds 
From SciSparc Ltd
Via GlobeNewswire
Israel-Based Clearmind Medicine Files Patent Applications for Three Unique Combinations of Future Psychedelic-Based Compounds
From Clearmind Medicine Inc.
Via GlobeNewswire
Why CVRx Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Arbe Robotics Ltd. (NASDAQ: ARBE) gained 62.8% to $7.08. Arbe Robotics is expected to report its financial results for the fourth quarter on Thursday, March 2, 2023. 
Via Benzinga
Why Owlet Shares Are Trading Higher By Over 45%; Here Are 20 Stocks Moving Premarket
Gainers Troika Media Group Inc (NASDAQ: TRKA) shares rose 65.9% to $0.37 in pre-market trading after dropping 4% on Friday. 
Via Benzinga
Why Universal Electronics Shares Are Trading Lower By 30%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Ibio Inc (NYSE: IBIO) shares rose 97% to $1.4787 after the company announced MUC16 as its latest immune-oncology target program. 
Via Benzinga
Why SciSparc Shares Are Moving During Friday's Session
SciSparc Ltd (NASDAQ: SPRC) shares are trading higher by 8.08% to $0.98 Friday morning, though off the session high of $1.33, after the company announced its MitoCareX Bio joint venture achieved... 
Via Benzinga
Why Is SciSparc (SPRC) Stock Up 14% Today?
SciSparc (SPRC) stock is taking off on Friday as investors react to an update on its drug development joint venture MitoCareX Bio. 
Via InvestorPlace
SciSparc's Drug Discovery Joint Venture MitoCareX Bio Successfully Reached First Milestone for its Future Machine Learning System
From SciSparc Ltd
Via GlobeNewswire
Novel Combination Of Cannabis-Like Compound With Classical Psychedelics Searches IP Coverage In US
Israeli-based next-gen psychedelics biotech Clearmind Medicine (NASDAQ: CMND) together with partner clinical-stage pharma company SciSparc (NASDAQ: SPRC) has filed three provisional patent applications... 
Via Benzinga
SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Three Provisional Patent Applications in the US
From SciSparc Ltd
Via GlobeNewswire
Israel-Based Clearmind Medicine Strengthening IP Portfolio with Three Provisional Patent Applications in the US
From Clearmind Medicine Inc.
Via GlobeNewswire
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.